Innocare
InnoCare is a commercial-stage Chinese biopharmaceutical company developing innovative therapies for hematological malignancies and autoimmune diseases, with three approved products and 13+ clinical-stage candidates spanning BTK, BCL2, TYK2, ADC, and bispecific antibody modalities.
- Company typePublic
- Founded2015
- HeadquartersChangping, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Innocare does
InnoCare (诺诚健华) is a commercial-stage Chinese biopharmaceutical company founded in 2015 by Dr. Jasmine Cui and structural biologist Professor Shi Yigong, dual-listed on the Hong Kong Stock Exchange (09969.HK) and Shanghai Stock Exchange STAR Market (688428.SH). The company focuses on developing innovative therapies for hematological malignancies and autoimmune diseases, operating an integrated platform that spans drug discovery, clinical development, GMP manufacturing, and direct commercialization. Its commercial portfolio includes three approved products: orelabrutinib (a highly selective covalent BTK inhibitor marketed as Yinuokai/宜诺凯 for CLL/SLL, MCL, and MZL with all indications on China's NRDL), tafasitamab (a CD19 monoclonal antibody licensed from Incyte for DLBCL, marketed as Mingnuokai/明诺凯), and zurletrectinib (a next-generation pan-TRK inhibitor for NTRK fusion-positive solid tumors approved December 2025). The clinical pipeline comprises 13+ candidates across BTK, BCL2, TYK2, IL-17, VAV1 molecular glue degrader, ADC, and bispecific antibody modalities, including several potentially first-in-class assets such as ICP-538 (first VAV1 degrader in clinical trials in China) and ICP-054 (potential first-in-category oral IL-17AA/AF inhibitor).
The company's revenue model combines direct-to-hospital product sales through an in-house commercialization team covering hundreds of hospitals across China, supplemented by out-licensing and milestone payments from international partners. Major 2025 transactions include the Zenas BioPharma deal for autoimmune rights to orelabrutinib (over US$2 billion total value, US$100 million upfront) and the Prolium Bioscience deal for the CD20xCD3 bispecific antibody ICP-B02 (US$520 million total plus equity). Products are sold under China's National Reimbursement Drug List framework, while ex-China commercialization proceeds via partnerships in Singapore, Australia, and broader Asian and US markets through the New Jersey/Boston office. R&D investment of approximately RMB 9.5 billion in 2025 reflects sustained pipeline funding, supported by a substantial cash position and the company's first full year of profitability in 2025 (revenue of RMB 2,375 million, up 135.3% year-on-year, with RMB 644 million net profit).
Innocare firmographics
Firmographics- Name
- Innocare
- Legal name
- 诺诚健华医药有限公司
- Website
- https://innocarepharma.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InnoCare is a commercial-stage Chinese biopharmaceutical company developing innovative therapies for hematological malignancies and autoimmune diseases, with three approved products and 13+ clinical-stage candidates spanning BTK, BCL2, TYK2, ADC, and bispecific antibody modalities.
- Ownership category
- akta.pro rank
Innocare industry classification
Industry- Product category
- Biopharmaceutical Oncology Drugs
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Innocare is headquartered
LocationHeadquarters
- HQ city
- Changping
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
Innocare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure, Others
Revenue model
- Product Sales - Orelabrutinib (Olabrubtinib): Revenue from sales of approved BTK inhibitor orelabrutinib (brand name Yinuokai/宜诺凯) in China, Singapore, and Australia. Multiple indications covered by national insurance including CLL/SLL, MCL, MZL.
- Product Sales - Tafasitamab: Revenue from CD19 monoclonal antibody tafasitamab (brand name Mingnuokai/明诺凯) approved for DLBCL, available in Hong Kong, Bo'ao, and Greater Bay Area.
- Product Sales - Zurletrectinib: Revenue from next-generation pan-TRK inhibitor zurletrectinib (ICP-723, brand name Yinuo Xin/宜诺欣) approved for NTRK fusion-positive solid tumors.
- Licensing and Milestone Payments: Revenue from out-licensing deals including Zenas BioPharma deal (over US$2 billion total value) for autoimmune pipeline, and Prolium Bioscience deal (US$520 million) for CD20xCD3 bispecific antibody.
- Milestone Payments from Collaboration: Upfront payments, development milestones, and royalties from various licensing and collaboration agreements with partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | National Reimbursement Drug List pricing |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
Innocare product offering
Product offeringCore offering
InnoCare is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative small molecule and biologic drugs for the treatment of hematological malignancies and autoimmune diseases. Its three marketed products are orelabrutinib (a BTK inhibitor sold under the Yinuokai brand), tafasitamab (a CD19 monoclonal antibody sold under the Mingnuokai brand), and zurletrectinib (a pan-TRK inhibitor sold under the Yinuoxin brand). The company maintains a pipeline of over 13 clinical-stage drug candidates and operates an integrated platform covering drug discovery, clinical development, manufacturing, and commercialization.
Product overview
InnoCare (诺诚健华) is a commercial-stage biopharmaceutical company with a comprehensive integrated platform spanning from源头创新 (origin innovation), clinical development, manufacturing to commercialization. The company has developed a robust product portfolio focused on malignant tumors (血液瘤) and autoimmune diseases (自身免疫性疾病). Three products have been approved and launched: Orelabrutinib (BTK inhibitor for hematological malignancies and autoimmune diseases), Tafasitamab (CD19 monoclonal antibody for DLBCL), and Zurletrectinib (pan-TRK inhibitor for NTRK fusion-positive solid tumors). The pipeline includes over 10 clinical-stage innovative drugs covering BTK, BCL2, TYK2, IL-17, VAV1, ADC, and bispecific antibody platforms. The company operates dual A+H listings (688428.SH, 09969.HK) and has achieved its first full year of profitability.
Differentiator
Problem solved
Functional benefit
Brands
- 宜诺凯 (Yinuokai): Brand name for orelabrutinib (BTK inhibitor) in China
- 明诺凯 (Mingnuokai)
- 宜诺欣 (Yinuoxin)
Products and services
- Orelabrutinib (奥布替尼, 宜诺凯, Yinuokai) A highly selective, covalent, irreversible oral BTK inhibitor developed for treating hematological malignancies (CLL/SLL, MCL, MZL) and autoimmune diseases (ITP, MS, SLE). Features high kinase selectivity reducing off-target effects with better efficacy and safety, achieving 100% BTK target binding with good PK characteristics.
- Tafasitamab (坦昔妥单抗, 明诺凯, Mingnuokai) A CD19-targeted humanized monoclonal antibody with optimized Fc domain that induces B-cell tumor lysis through apoptosis and immune effector mechanisms. Approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide.
- Zurletrectinib (佐来曲替尼, 宜诺欣, Yinuoxin, ICP-723) A next-generation pan-TRK inhibitor that effectively inhibits TRKA, TRKB, TRKC and overcomes resistance mutations including G595R and G667C. Approved for NTRK fusion-positive solid tumors in adult and pediatric patients.
Quantifiable outcome
- Orelabrutinib achieved 100% ORR in treatment-naïve CLL/SLL patients with 94.4% 36-month PFS rate at median 38.1 months follow-up
- +4 more outcomes
Companies that use Innocare
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Innocare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Innocare partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major, core/flagship and minor.
- Zenas BioPharma (ZB021/ICP-054 partnership)majorPhase 1 clinical trial collaboration for oral IL-17AA/AF inhibitor ICP-054 (ZB021) in China. Both companies conducting SAD and MAD studies in healthy volunteers with data expected by end of 2026. Zenas holds ex-Greater China and Southeast Asia rights from original licensing deal.
- Zenas BioPharmacore/flagshipMajor licensing agreement where Zenas acquired global development and commercialization rights for orelabrutinib in multiple sclerosis and non-oncology autoimmune indications. Deal includes $100 million upfront plus stock and milestones worth over $2 billion total. InnoCare retains oncology rights globally and autoimmune rights in Greater China and Southeast Asia. Zenas also licensed rights to oral IL-17 AA/AF inhibitor and brain-penetrating TYK2 inhibitor.
- Prolium BiosciencemajorLicensing deal for CD20xCD3 bispecific antibody ICP-B02 (CM355) in global non-oncology and ex-Asia oncology fields. Deal valued at up to $520 million plus minority equity stake. InnoCare and Keymed to receive upfront, milestones, and tiered royalties on net sales.
- Keymed Biosciences (康诺亚)core/flagshipJoint development partnership for CD3xCD20 bispecific antibody ICP-B02 (CM355). Both companies and their joint venture partnered with Prolium for global licensing. Keymed and InnoCare jointly developed the bispecific antibody for hematological malignancies and autoimmune diseases.
- ArriVent BiopharmaminorClinical collaboration announced in 2023 milestone timeline. Specific collaboration details not detailed in available sources.
- IncytemajorLicensing agreement for tafasitamab development and commercialization in Greater China (mainland China, Hong Kong, Macau, Taiwan). InnoCare received $35 million upfront and up to $82.5 million in development, registration and commercialization milestones plus tiered sales royalties. InnoCare holds exclusive commercialization rights in Greater China.
Scale indicators11 records
Recent moves9 records
Expansion highlights7 records
Innocare competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca (Calquence/acalabrutinib): Global pharma whose acalabrutinib is a major second-generation BTK inhibitor competing directly with orelabrutinib in hematological malignancies worldwide. Relevant as the global benchmark for BTK inhibitor commercialization.
- Hansoh Pharmaceutical Group: One of China's largest domestic innovative pharmaceutical companies with broad oncology and specialty pharma portfolio. Larger and more diversified than InnoCare, but competes in overlapping therapeutic areas.
- Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with extensive oncology pipeline and broad therapeutic coverage. Serves as the dominant domestic incumbent against which Chinese biopharmas like InnoCare compete.
- AbbVie / Johnson & Johnson (Imbruvica/ibrutinib): First-generation BTK inhibitor ibrutinib established the BTK market in hematology. Relevant as the legacy standard against which InnoCare's selective orelabrutinib differentiates on safety and selectivity.
Direct peers
- Zai Lab Limited: US/HK-listed Chinese biopharma with a licensing-driven business model bringing innovative therapies to China. Comparable go-to-market strategy and oncology/autoimmune focus, though Zai Lab is more partner-dependent.
- Shanghai Junshi Biosciences: Chinese innovative biopharma with A+H dual listing developing oncology and autoimmune therapeutics. Overlapping therapeutic focus areas and similar China-to-global commercialization trajectory as InnoCare.
- Akeso, Inc. Chinese biopharma specializing in bispecific antibodies and immuno-oncology, with similar integrated R&D and commercialization platform. Akeso's bispecific antibody pipeline is directly comparable to InnoCare's CD3xCD20 program (ICP-B02).
- BeOne Medicines (formerly BeiGene): BeOne's zanubrutinib (Brukinsa) is a direct BTK inhibitor competitor to orelabrutinib in hematological malignancies. Both are Chinese-founded biopharmas with global commercialization ambitions and dual US/China listings, making BeOne the most directly comparable peer.
- Hutchmed (China) Limited: Hong Kong-listed Chinese biopharma with integrated discovery-to-commercialization platform focused on oncology and autoimmune diseases. Similar target indications (solid tumors, hematological cancers) and business model as InnoCare, with comparable scale and pipeline depth.
Emerging players
- Keymed Biosciences: Co-developer of CD3xCD20 bispecific antibody ICP-B02 (CM355) with InnoCare. Smaller and more focused than InnoCare but directly relevant as a bispecific antibody specialist and direct collaboration partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Innocare social profiles
Digital presenceInnocare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Innocare leadership team
Management profileNumber of profiles
Profiles18 records
Innocare subsidiaries and ownership
Company hierarchySubsidiaries4 records
Innocare funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Innocare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Innocare
What does Innocare do?
InnoCare is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative small molecule and biologic drugs for the treatment of hematological malignancies and autoimmune diseases. Its three marketed products are orelabrutinib (a BTK inhibitor sold under the Yinuokai brand), tafasitamab (a CD19 monoclonal antibody sold under the Mingnuokai brand), and zurletrectinib (a pan-TRK inhibitor sold under the Yinuoxin brand). The company maintains a pipeline of over 13 clinical-stage drug candidates and operates an integrated platform covering drug discovery, clinical development, manufacturing, and commercialization.
Is Innocare a public or private company?
Innocare is a public company. It is classified as public and is currently operating.
When was Innocare founded?
Innocare was founded in 2015. It employs 11 to 50 people.
Where is Innocare based?
Innocare is headquartered in Changping, China, in the Asia region.
How does Innocare make money?
Five revenue lines are on record. Product Sales - Orelabrutinib (Olabrubtinib) is the primary driver. The others are product Sales - Tafasitamab, product Sales - Zurletrectinib, licensing and Milestone Payments and milestone Payments from Collaboration.
Who are Innocare's main competitors?
Broad incumbents on record are AstraZeneca (Calquence/acalabrutinib), Hansoh Pharmaceutical Group, Jiangsu Hengrui Pharmaceuticals and AbbVie / Johnson & Johnson (Imbruvica/ibrutinib). Direct peers are Zai Lab Limited, Shanghai Junshi Biosciences, Akeso, Inc., BeOne Medicines (formerly BeiGene) and Hutchmed (China) Limited. Keymed Biosciences is listed as an emerging player.
Does Innocare have an API?
No public API is recorded for Innocare.
What industry is Innocare in?
Innocare's product category is Biopharmaceutical Oncology Drugs. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 3254 and its SIC code is 2834.